Cure8 news brief
If true, the tripartite circuit model helps explain why some patients respond to therapies that target one pathway while others do not — because other nodes in the loop may sustain disease.
Understanding interactions among the barrier, immunity, and microbes could lead to combination or multi-pronged treatment strategies.
Adults with Crohn’s disease, clinicians treating IBD, and researchers studying mucosal immunity or the gut microbiome.
A new narrative review synthesizes mechanistic studies, clinical trials and literature (2009–2025) proposing a tripartite feedback-loop model linking epithelial barrier dysfunction, immune dysregulation, and microbiota changes as interconnected drivers of Crohn’s disease.
The authors describe three reinforcing circuits (IL-23/Th17, TNF-alpha/NF-kappaB, and SCFA-depletion) and discuss how this framework helps explain variable responses to targeted therapies.
The review cites clinical trial evidence supporting targeted drugs — for example, the IL-23 inhibitor risankizumab and the JAK1 inhibitor upadacitinib — and highlights non-drug approaches such as the Crohn’s Disease Exclusion Diet.
It also notes cellular signaling pathways (NF-kappaB, Notch, PI3K/Akt) and microbial metabolites (short-chain fatty acids) as mechanistic links. This brief summarizes the review’s main framing and reported clinical trial examples without endorsing treatments or providing medical advice.
This article is a narrative review summarizing published mechanistic studies and trials through 2025; it synthesizes existing evidence rather than reporting new clinical trial results. Individual treatment decisions should be made with a clinician. The review highlights hypotheses and frameworks that require further testing in prospective studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
